Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00287066 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 22
- Enrollment target
NCT00287066: Clinical Trial Phase 3 study, sponsored by Pfizer.
NCT00287066 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 22 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00287066, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 22 participants
- Enrollment target
Study Summary
To assess the impact of inhalation of insulin on glucose disposition in patients with type 1 diabetes
Interventions
- DRUG Regular Human Insulin
- DRUG Inhaled Human Insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
Why NCT00287066 stopped before completion
NCT00287066 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Regular Human Insulin is the first listed.
NCT00287066 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00287066 about?
NCT00287066 is a clinical study titled "A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition". To assess the impact of inhalation of insulin on glucose disposition in patients with type 1 diabetes
What is the current status of trial NCT00287066?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 22 participants. The study started on 2006-02. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00287066?
The interventions under investigation include: Regular Human Insulin (DRUG), Inhaled Human Insulin (DRUG).
Who is sponsoring clinical trial NCT00287066?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00287066's enrollment target sits among peer trials
22 1953rd of 2000 higher than 48 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia